Sales grew 4.3% in CHF (7.3% in local currencies) to CHF 326.4m, driven by CMC Development, while EBITDA margin declined to 25.4%. Outlook for 2026 anticipates 35–40% sales growth and EBITDA margin in the low thirties, supported by strong peptide and oligo demand.Original document: Bachem Holding A…
Sales grew 4.3% in CHF (7.3% in local currencies) to CHF 326.4m, driven by CMC Development, while EBITDA margin declined to 25.4%. Outlook for 2026 anticipates 35–40% sales growth and EBITDA margin in the low thirties, supported by strong peptide and oligo demand.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
